Amylyx Pharmaceuticals, Inc.
AMLXAmylyx Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel therapies for endocrine conditions and neurodegenerative diseases with high unmet medical needs.
Earnings
Next report
Nov 5, 2026 (in 2 months)Financials
Q2 2026Valuation & ratios
Competitors
By market cap
By net margin
Profile
Amylyx Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel therapies for endocrine conditions and neurodegenerative diseases with high unmet medical needs. The company utilizes a pipeline strategy that matches investigational therapies with specific diseases based on mechanistic rationales, biomarkers, and rigorous preclinical data. Its primary value proposition lies in advancing first-in-class and oral fixed-dose combination assets through late-stage clinical trials to address rare and debilitating disorders.
Amylyx is a clinical-stage developer with multiple orphan drug and breakthrough therapy designations, competing against major pharmaceutical firms through specialized focus on niche rare disease populations.
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s market cap?
- Amylyx Pharmaceuticals, Inc. (AMLX) has a market capitalization of $3.6B and trades on NASDAQ.
- Who are Amylyx Pharmaceuticals, Inc.'s competitors?
- Amylyx Pharmaceuticals, Inc.'s key competitors include Viking Therapeutics, Inc, MBX Biosciences, Inc. Common Stock, Biomea Fusion, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Amylyx Pharmaceuticals, Inc. partner with?
- Amylyx Pharmaceuticals, Inc.'s notable partners include Gubra A/S, Breakthrough T1D, Stanford University, and others.
- Where is Amylyx Pharmaceuticals, Inc. headquartered?
- Amylyx Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 384 people. It has been publicly traded since 2022.